MétaCan
Menu
Back to cohort

MP24-10 NO SURVIVAL DIFFERENCE BETWEEN PATIENTS WITH DE NOVO MUSCLE-INVASIVE BLADDER CANCER COMPARED TO THOSE THAT PROGRESS IN ROUTINE CLINICAL PRACTICE

2020· article· en· W3022147006 on OpenAlexaboutno aff
Avril Lusty, D. Robert Siemens, Christopher Booth

Bibliographic record

VenueThe Journal of Urology · 2020
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineBladder cancerCystectomyConfoundingProportional hazards modelDiseaseCancerInternal medicinePopulationCancer registryOncologyStage (stratigraphy)Retrospective cohort studyStatistical significance

Abstract

fetched live from OpenAlex

INTRODUCTION AND OBJECTIVE: Although consensus frequently suggests that patients who progress to muscle-invasive bladder cancer (MIBC) have worse outcomes than those that present de novo, contemporary studies have been equivocal. The concept is important not only with respect to understanding the biology of the disease but also clinical decision making. The primary objective of this study was to determine if there is a difference in cancer-specific (CSS) and overall survival (OS) between radical cystectomy (RC) patients who presented either with de novo MIBC or those patients who progressed to MIBC. METHODS: This retrospective population-based study reports early and late outcomes of all patients treated within Ontario during 2009-2013 based on their presentation of bladder cancer (de novo vs. progression from non-invasive disease). All incident cases that underwent RC were identified using the Ontario Cancer Registry (OCR) and linked to treatment records. Records from the Canadian Institute for Health Information were used to identify those patients treated with RC. As stage of disease was not routinely available, a team of trained data abstractors obtained and reviewed surgical pathology reports for all RC cases. Statistical analysis of the survival data was performed using the Kaplan-Meier method and Cox proportional hazards were used to adjust for known confounders. RESULTS: 1573 patients underwent RC between 2009 and 2013 in the province of Ontario. 893 were diagnosed with de novo MIBC and 79% had clinical T2 or greater disease at the time of TURBT. 680 were identified as progressors, and 49% had clinical T2 or greater disease at the time of TURBT. Further, neoadjuvant chemotherapy was received by 17% and 13% of de novo patients and progressors respectively. Several process indicators and early outcomes spread to be equivalent between the cohorts including 30 day mortality with a hazard ratio of 1.69 (95% CI 0.90-3.19). There was improved CSS and OS for progressors compared to de novo MIBC patients with hazard ratios of 0.85 (95% CI 0.74-0.98) and 0.90 (95% CI 0.79-1.03) respectively in unadjusted analysis for the whole cohort. However, when controlled for patients with only clinical T2 or greater disease, there was no difference in either CSS or OS between groups in adjusted analysis. CONCLUSIONS: This study shows, when controlled for clinical stage, no significant difference in CSS or OS between patients with de novo MIBC and progressors of MIBC in routine clinical practice. Source of Funding: none

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.065
Threshold uncertainty score0.129

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.075
GPT teacher head0.376
Teacher spread0.301 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of UrologySame topicBladder and Urothelial Cancer TreatmentsFrench-language works237,207